Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

To assess the level of activity and toxicity of gefitinib (ZD1839, Iressa™) in a population of patients with locally recurrent and/or metastatic head and neck cancer. Patients were recruited into an expanded access programme through the multidisciplinary head and neck clinics at the Royal Marsden an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kirby, A M, A'hern, R P, D'ambrosio, C, Tanay, M, Syrigos, K N, Rogers, S J, Box, C, Eccles, S A, Nutting, C M, Harrington, K J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2006
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361202/
https://ncbi.nlm.nih.gov/pubmed/16495923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602999
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller